Timber Pharmaceuticals Presents at EADV’s 30th Anniversary Congress
October 01, 2021 08:00 ET
|
Timber Pharmaceuticals
Basking Ridge, N.J., Oct. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021 17:58 ET
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
August 24, 2021 08:00 ET
|
Timber Pharmaceuticals
- Topline results expected to be announced in the fourth quarter of 2021 - - Company preparing for an End-of-Phase 2 meeting with the FDA - Basking Ridge, N.J., Aug. 24, 2021 (GLOBE...
Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results
August 10, 2021 08:00 ET
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Announces Adjournment of Annual Meeting
June 03, 2021 16:05 ET
|
Timber Pharmaceuticals
Basking Ridge, NJ, June 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis
May 26, 2021 16:05 ET
|
Timber Pharmaceuticals
- Company plans to ask for end-of-Phase 2 meeting with FDA by end of 2021 - Basking Ridge, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or...
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results
May 11, 2021 16:39 ET
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Receives Decision to Grant Japanese Patent for Lead Asset TMB-001
April 28, 2021 08:00 ET
|
Timber Pharmaceuticals
- Company is evaluating a topical pharmaceutical composition of isotretinoin for the treatment of moderate to severe subtypes of congenital ichthyosis - Basking Ridge, NJ, April 28, 2021 ...
Timber Pharmaceuticals Announces Appointment of John Koconis as Chairman of the Board of Directors
April 23, 2021 08:00 ET
|
Timber Pharmaceuticals
- Edward J. Sitar appointed as Lead Independent Director of the Board - - Company establishes Science and Technology Committee to be chaired by Dr. David Cohen - Basking Ridge, NJ, April 23,...
Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings
April 02, 2021 16:05 ET
|
Timber Pharmaceuticals
Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the...